SLS
SELLAS Life Sciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 1
RSI Overbought
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About SLS
Sellas Life Sciences Group, Inc.
A late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States
Pharmaceutical
04/03/2006
03/12/2008
NASDAQ Stock Exchange
15
12-31
Common stock
7 Times Square, Suite 2503, New York, NY 10036
--
SELLAS Life Sciences Group, Inc., was incorporated in Delaware on April 3, 2006 as Argonaut Pharmaceuticals, Inc. In December 2017, the Company completed a business combination with a privately held Bermuda exempted company and changed its name to "SELLAS Life Sciences Group, Inc.". The company is a late-stage clinical biopharmaceutical company focused on developing new therapies for a variety of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy for nephroblastoma 1 or WT1 antigen, and GFH009, a highly selective small molecule cyclin-dependent kinase 9, or CDK 9 inhibitor. The company's lead product candidate, GPS, a cancer immunotherapy agent licensed from Memorial Sloan Kettering Cancer Center (MSK), targets the WT1 protein, which is present in 20 or more cancer types. Based on its mechanism of action as a direct immune agent, GPS has the potential to be used as monotherapy or in combination with immunotherapeutics to address a wide range of hematological, or hematological, cancer and solid tumor indications.
Company Financials
EPS
SLS has released its 2024 Q4 earnings. EPS was reported at -0.08, versus the expected -0.11, beating expectations. The chart below visualizes how SLS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available